Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
plus
Actualités sur Medizin, Gesundheit
Schweizerischer Nationalfonds / Fonds national suisse
The Covid-19 pandemic is preparing us for future crises
Bern (ots) - The SNSF Corona Research Conference shows how the Covid-19 pandemic has enabled us to accumulate knowledge that will be useful in dealing with future crises. "If we ever have to deal with a new pandemic in future we will not be starting from scratch, as was the case when we were confronted with the coronavirus." These are the words of scientist Barbara Rath. As an active participant in the Vienna Vaccine ...
plusHovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...
plusGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
plusHuma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis
New York and London (ots/PRNewswire) - - Project aims to improve patient outcomes through better clinical management of disease exacerbations using self-reported data - Exciting opportunity to improve education and empowerment and for patients to be active participants in their own care - Huma's EU MDR Class IIb ...
plusAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
plusEuro Airport Basel-Mulhouse-Freiburg
Annual Report 2022: a return to a stable financial position
plusAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
plus- 3
HIN Trust Circle, now powered by SCION
plus Schweizerischer Nationalfonds / Fonds national suisse
Traffic noise - the enemy of our brains
plusInternational Society of Nephrology (ISN)
INTERNATIONAL SOCIETY OF NEPHROLOGY LAUNCHES GLOBAL KIDNEY HEALTH REPORT THAT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE
Brussels (ots/PRNewswire) - Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health ...
plusBeVinced launches MedTech CRO services
Amsterdam (ots/PRNewswire) - BeVinced, a new leading Clinical Research Organization (CRO) specializing in Medical Device Regulation (MDR) compliance services, is proud to announce the launch of its services aimed at addressing the unique needs of the medical device industry. The company was started by two recognized experts in the MedTech CRO arena: Joris Bannenberg and Dirk Meijer, both MD. They founded Factory CRO in ...
plusALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test
Paris and Milan (ots/PRNewswire) - - An estimated 2.3% of the European population is affected by bipolar disorder (BD)[1], a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis[2] - To date, the diagnosis of BD is based on a psychiatric clinical ...
plusHuma receives world's first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform
New York and London (ots/PRNewswire) - - Huma's platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health innovation across the industry - Class IIb certification expands the patient population and level of disease severity that ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
plusHovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple's Epidel® technology ...
plusFDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health / Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population
plusPolytex launches new PRO line - the next-generation full cycle workwear solution
Caesarea, Israel (ots/PRNewswire) - With varied dispensing and return units linked to advanced, cloud-based management software, the new Polytex PRO line offers higher performance, an improved user experience, and enhanced cyber security. Israeli workwear management company Polytex Technologies today announced the launch of its next-generation full cycle workwear ...
plusREVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY
Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...
plusMedison Pharma; Alnylam Pharmaceuticals
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...
plusIktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutions
Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...
plusServier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio
Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop ...
plusHovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise
Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Big data, big challenges
Bern (ots) - If handled responsibly, big data enables many useful applications: the National Research Programme "Big Data" (NRP 75) of the Swiss National Science Foundation investigated the opportunities and the challenges. The use of big data can improve our everyday lives: medical care, mobility and energy efficiency, or the supply of information. At the same time, the increasing use of big data poses a challenge - in terms of safeguarding democratic processes, equal ...
plusDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
plusEW Nutrition showcases customer-focused solutions for the animal nutrition industry at VIV Asia 2023
Singapore (ots) - EW Nutrition will participate in VIV Asia 2023 to showcase its newest solutions for the animal nutrition industry. “We are constantly innovating to provide best-in-class products and programs. Our participation in VIV Asia 2023 is a good opportunity to connect with our partners over EW ...
plusIris. smart ring | Elevate style. Embrace self-awareness.
plusSchweizerischer Nationalfonds / Fonds national suisse
Brain scans of people with MS help us understand the effects of Covid
Bern (ots) - People affected by multiple sclerosis need to undergo regular MRI brain scans. The images are now being used to visualise the effects of a coronavirus infection. Brain fog, memory problems, loss of the sense of smell - Covid-19 affects the brain in a number of ways, yet the mechanisms behind this remain largely unknown. This is because disease-related changes in our brains are almost impossible to detect if ...
plusServier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...
plus
Précédent12345678910Suivant